Spotlight on Neurology

Credits: 0.75 CME
Conference Updates in SMA
Gyula Acsadi, MD, PhD
The France Foundation

Conference Updates in SMA

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credits
Released: November 6, 2018
Expires: November 5, 2019
45 minutes to complete

Accredited By

Target Audience

Pediatric Neurologists, Neurologists, Neuromuscular Specialists, Pediatricians

Learning Objectives

  • Review new information on the management of patients with SMA released at the Child Neurology Society and World Muscle Society 2018 annual meetings
  • Apply new information to current SMA management practices, as relevant

Activity Description

Experts in spinal muscular atrophy (SMA) attended October neurologic and neuromuscular meetings. These short videos share the exciting information from the meetings in easily digestible segments with insight in how this new information may change the management of patients with SMA.

Statement of Educational Need

The recent, rapid influx of information surrounding approved and emerging treatments for spinal muscular atrophy (SMA) has created a gap in clinician knowledge and the ability to apply it to practice.

Agenda

New Therapies are Changing the Outcomes of SMA (2:53)
Dr. Thomas Crawford

NURTURE Update in Presymptomatic Patients (3:35)
Dr. Nancy Kuntz and Dr. Richard Finkel

Nusinersen Treated Type 1 Patients Older Than 7 Months (4:18)
Dr. Laurent Servais

Results in Type 3 Patients Treated with Nusinersen (3:05)
Dr. Richard Finkel, Dr. Nancy Kuntz, and Dr. Gyula Acsadi

A Multidisciplinary Team is Essential to the Management of SMA (2:08)
Dr. Thomas Crawford and Dr. Laurent Servais

Updates on SMA from Chicago (4:20)
Dr. Richard Finkel

SMA Poster Highlights from Mendoza (4:43)
Dr. Laurent Servais

How a Neurofilament Biomarker Could Change SMA Management (6:41)
Dr. Thomas Crawford

Improvement for Patients in ENDEAR Study (4:07)
Dr. Nancy Kuntz and Dr. Richard Finkel

Emerging Data from Gene Therapy Trials (2:44)
Dr. Richard Finkel and Dr. Gyula Acsadi

Oral Small Molecules as an Emerging Therapy for SMA (3:45)
Dr. Richard Finkel

Caution in Counseling Patients with SMA (3:12)
Dr. Thomas Crawford and Dr. Laurent Servais

Early Diagnosis and Treatment are Essential (4:23)
Dr. Gyula Acsadi, Dr. Nancy Kuntz, and Dr. Richard Finkel

Faculty

Gyula Acsadi, MD, PhD
Division Head of Neurology and Rehabilitation
Professor of Pediatric Neurology
Connecticut Children’s Medical Center
University of Connecticut Medical School
Farmington, Connecticut
  • Dr. Acsadi serves as a consultant for AveXis, Biogen, and Sarepta. He is on the speakers bureau for Biogen and conducts contract research for Biogen, Italfarmaco, and Sarepta.


Thomas Crawford, MD
Co-Director, Muscular Dystrophy Association Clinic
Professor of Neurology
Johns Hopkins Medicine
Baltimore, Maryland
  • Dr. Crawford serves as a consultant and is on the advisory boards for AveXis, Biogen, Mallinckrodt, Marathon, Roche/Genentech, Santhera, and Scholar Rock.


Richard S. Finkel, MD
Division Chief of Neurology
Pediatric Neurology
Nemours Children’s Hospital
Orlando, Florida
  • Dr. Finkel is a consultant for AveXis, Biogen, Catabasis, Ionis, Mitobridge, Roche, and Novartis. He receives clinical trial support from AveXis, Biogen, Ionis, Catabasis, Cytokinetics, Lilly, MDA, NIH, ReveraGen, and Summit. Dr. Finkel owns stock in Roche. His partner holds several patents and receives patent licensing royalties from National Jewish Center and Children’s Hospital of Philadelphia.


Nancy L. Kuntz, MD
Professor of Pediatrics and Neurology
Northwestern University Feinberg School of Medicine
Attending Physician
Division of Neurology
Ann & Robert H. Lurie Children’s Hospital of Chicago
Chicago, Illinois
  • Dr. Kuntz serves on clinical advisory boards for Audentes, AveXis, Biogen, Roche, and Sarepta. She has participated in educational lectures funded by Biogen.


Laurent Servais, MD, PhD
Pediatric Neurology
Institut de Myologie
Paris, France
  • Dr. Servais serves on advisory boards for AveXis, Biogen, and Roche. He is a principle investigator for projects funded by AveXis, Biogen, and Roche.


Conflict of Interest Policy/Disclosure Statement

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Instructions for Receiving Credit

  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME/CE information.
  3. Complete the CME/CE activity.
  4. Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
  6. Credit documentation/reporting:

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Neurology Presentations

1.00 CME
Forefront Collaborative
Rethinking Migraine Treatment: New Therapies Impacting Patient Care

Rethinking Migraine Treatment: New Therapies Impacting Patient Care

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: July 15, 2019
Expires: July 14, 2020
60 minutes to complete

Accredited By

Target Audience

This activity is designed for general neurologists and headache specialists. Other healthcare professionals, including physician assistants, nurse practitioners, nurses, and pharmacists, who treat patients with headache may also benefit from participation in the educational activity.

Learning Objectives

Upon completion of this activity, participants should be able to:

  1. Describe new advances in the pathophysiology of migraine, a chronic neurologic disease.
  2. Develop treatment plans in line with standards of practice for acute and preventive management of episodic and chronic migraine.
  3. Discuss unmet patient needs and burden of episodic and chronic migraine.
  4. Analyze safety and efficacy data for emerging therapies in acute and preventive treatment of migraine relative to current standards and clinically meaningful outcomes.

Activity Description

The thinking around both preventive and acute treatment of migraine is undergoing a radical change as new therapies emerge that target varied routes, some specific to known mechanisms of migraine pathophysiology. From new classes of treatment to emerging therapies and neuromodulatory devices, headache specialist and general neurologist, Stewart J. Tepper, MD, and Ana Felix, MD, FAAN, team up to provide a practical update for practicing clinicians on key treatment advances that are transforming migraine care.

Statement of Educational Need

With the recent approvals, neurologists are faced with two challenges: staying abreast of the rapidly expanding evidence base to inform acute and preventive treatment of migraine (knowledge-based gaps) and interpreting data of approved and investigational therapies to best guide clinical decision-making (competency-based gaps).

Agenda

The New Era of Migraine Treatment
Cases in Episodic and Chronic Migraine

Faculty

Stewart J. Tepper, MD
Professor of Neurology,
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire


Ana Felix, MD, FAAN
Neurologist,
Assistant Professor,
Department of Internal Medicine
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina


Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Faculty: Stewart J. Tepper, MD, has received salary from Dartmouth-Hitchcock Medical Center and from the American Headache Society and royalties from Springer; he has been a consultant or on an advisory board for Acorda Therapeutics, Alder BioPharmaceuticals, Alexza Pharmaceuticals, Inc, Allergan, Alphasights, Amgen, Autonomic Technologies, Inc., Axsome Therapeutics, Cefaly, Charleston Laboratories, Inc., DeepBench, Dr. Reddy’s Laboratories Ltd., electroCore, LLC, Eli Lilly and Company, eNeura, GLG Pharma, Guidepoint Global, LLC, Magellan Rx Management, Neurolief Ltd., Nordic BioTech, Novartis, Pfizer, Scion Neurostim, LLC, Slingshot Insights, Supernus Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Zosano Pharma Corporation; Dr. Tepper has contracted research for Alder BioPharmaceuticals, Allergan, Amgen, Autonomic Technologies, Inc., Dr. Reddy’s Laboratories, Ltd., electroCore, LLC, eNeura, Neurolief, Novartis, Scion Neurostim, LLC, Teva Pharmaceutical Industries Ltd., and Zosano Pharma Corporation; he has ownership interest in Autonomic Technologies, Inc.
  • Planner (Forefront Collaborative): Lily Zurkovsky, PhD, has disclosed that she has personal stock in Teva PharmaceuticalIndustries Ltd.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this continuing education activity:

  • Faculty: Ana Felix, MD, FAAN
  • Planner (Forefront Collaborative):Krista Jaworski

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Forefront Collaborative designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

Participants must complete and submit the online CME evaluation form at the conclusion of the activity and achieve a passing score of 80%. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.

Content Review Statement

The content of this activity was independently peer reviewed. The reviewer of this activity has no relevant financial relationships to disclose.

This continuing medical education activity will include reference to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions about the Activity

Krista_jaworski@forefrontcollab.com
812-340-4274

1.25 CME / CE
The France Foundation
Are You Ready for Gene Replacement Therapy? Example from Spinal Muscular Atrophy

Are You Ready for Gene Replacement Therapy? Example from Spinal Muscular Atrophy

Start

Activity Details

Free CME/CE
1.25 AMA PRA Category 1 Credit(s)
Genetic Counselor CEUs
Released: June 3, 2019
Expires: June 2, 2020
1.25 hours to complete

Accredited By

Target Audience

U.S. geneticists and genetic counselors
International neurologists, pediatricians and geneticists

Learning Objectives

  • Explain the genetic aspects of SMA
  • Review the recessive nature of SMA
  • Discuss SMA carrier status
  • Discuss genetic screening recommendations
  • Explain status of newborn testing addition to screening panel
  • List states that have added newborn SMA testing
  • Explore the potential implications of gene replacement therapy for SMA
  • Summarize key clinical trial data on available/emerging treatments for SMA

Activity Description

Gene replacement therapy is gaining FDA approval in several therapeutic areas. In this roundtable discussion, three clinicians explain the different types of gene therapy and discuss risks and clinical trial results using spinal muscular atrophy (SMA) as an example.

Statement of Educational Need

Gene therapy is still a mystery to most clinicians. New therapies, such as gene therapy, prompt a reevaluation of the standards of care for patients with spinal muscular atrophy (SMA). Many clinicians have questions regarding SMA genetics.

Agenda

  • A Patient’s Story
  • Genetics of SMA
  • Screening and Genetic Testing
  • Treatment Options
  • Gene Therapy 101
  • Gene Replacement Therapy in SMA
  • Panel Discussion of Common Questions

Faculty

Wendy K. Chung, MD, PhD
Kennedy Family Professor of Pediatrics and Medicine
Columbia University
New York, NY
  • No relevant financial relationships to disclose


Melissa A. Gibbons, MS, CGC
Assistant Professor
Department of Pediatrics
University of Colorado School of Medicine
Children’s Hospital Colorado
Aurora, CO
  • Melissa Gibbons, MS, CGC, serves on advisory boards for Sarepta and AveXis.


Vamshi K. Rao, MD
Attending Physician, Neurology
Ann & Robert H. Lurie Children’s Hospital of Chicago
Assistant Professor of Pediatrics
Northwestern University
Feinberg School of Medicine
Chicago, IL
  • Vamshi Rao, MD, serves on the advisory board for AveXis and is a principal investigator for a clinical trial for NS Pharma.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in healthcare and not those of a commercial interest.

Activity Staff Disclosures
The planners, reviewers, editors, staff, CME/CE committee or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Genetic Counselor CEUs
The National Society of Genetic Counselors (NSGC) has authorized The France Foundation to offer up to 0.1 CEUs or 1 Category 1 contact hour for the activity Are You Ready for Gene Replacement Therapy? Example from SMA. The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of genetic counselor certification and recertification.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Method of Participation/How to Receive Credit

  • There are no fees for participating in and receiving AMA PRA Category 1 Credit. The first 50 participants requesting NSGC CEUs are free. All others must submit $25 payment. Instructions will be sent with a link for payment within a month of completing the activity.
  • Review the activity objectives and CME/CE/CEU information.
  • Participate in the CME/CE/CEU activity.
  • Complete the CME/CE/CEU evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect his/her professional practice, the quality of the instructional process, the perception of enhanced professional effectiveness, the perception of commercial bias and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting CME or CE credit, your certificate of credit or certificate of participation will be immediately available for download.
    • If you are requesting NSGC CEU credit, The France Foundation will submit all documentation of activity completion to NSGC. Your CEU certificate will be issued by the end of the calendar year in which you complete the activity. Please note that your NSGC User ID is required to claim credit. Visit www.nsgc.org to find your user ID.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis, Inc.

Disclosure of Unlabeled Use

TFF requires CME/CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Disclaimer

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Contact Information

If you have questions about this CME/CE activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

1.25 CME / CNE
Vindico
Applying New Guidelines, Imaging, and Insights on Extending the Treatment Window in Acute Ischemic Stroke

Applying New Guidelines, Imaging, and Insights on Extending the Treatment Window in Acute Ischemic Stroke

Start

Activity Details

Free CME/CNE
1.25 AMA PRA Category 1 Credit(s)
1.25 contact hours
Released: April 5, 2019
Expires: April 4, 2020
1.25 hours to complete

Accredited By

This continuing education activity is provided by Vindico Medical Education.

Target Audience

The intended audience for this activity is neurologists, cardiologists, nurses, and other health care professionals involved in the treatment of patients with acute ischemic stroke.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

Physicians

  • Apply recently revised guidelines for the appropriate prehospital management, diagnosis, and treatment of patients with suspected acute ischemic stroke (AIS).
  • Examine current practices for treatment of AIS in patients who present outside the recommended time limit for thrombolysis.
  • Incorporate the use of image-guided treatment to improve outcomes in patients with AIS.

Nurses

  • Apply recently revised guidelines for the appropriate prehospital management, diagnosis, and treatment of patients with suspected acute ischemic stroke (AIS).
  • Examine current practices for treatment of AIS in patients who present outside the recommended time limit for thrombolysis.
  • Assess the use of image-guided treatment to improve outcomes in patients with AIS.

Activity Description

Based on the success of several new clinical trials, the American Heart Association/American Stroke Association released updated stroke treatment guidelines in 2018. The guidelines address prehospital management, diagnosis, and treatment. Key revisions include extending the treatment window for mechanical thrombectomy in eligible patients and broadening the number of patients who qualify for thrombolysis. Advances in imaging techniques and technology have improved the overall management of acute ischemic stroke (AIS), and physicians must keep apprised of how to best incorporate these findings into practice to improve patient care. This CME/CNE activity will review the revised guidelines for patients with suspected AIS and patients who present outside the recommended time limit for thrombolysis, as well as the use of image-guided treatment to improve outcomes.

Faculty

Activity Chair

Philip B. Gorelick, MD, MPH
Adjunct Professor, Davee Department of Neurology
Division of Vascular Neurology
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosures
No relevant financial relationships to disclose.


Faculty

Gregory W. Albers, MD
Director, Stanford Stroke Center
Coyote Foundation Professor of Neurology and
Neurological Sciences
Stanford University Medical Center
Stanford, CA
Disclosures
Consulting Fee: Genentech, iSchemaView, Medtronic
Ownership Interest: iSchemaView


Edward C. Jauch, MD, MS
Chief of System Research
Mission Research Institute/Mission Health
Asheville, NC
Disclosures
Consulting Fee: Biogen


Christopher A. Lewandowski, MD
Executive Vice Chair, Department of Emergency Medicine
Henry Ford Health System
Clinical Professor of Emergency Medicine, Wayne State University
Detroit, MI
Disclosures
Consulting Fee: Shire
Research Funding: NIH


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Maria Gannett, MSN, CRNP
No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.

Staff
Vindico Medical Education
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center (ANCC) Commission on Accreditation’s Standards for Commercial Support, all CME/CNE providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers and staff involved in the development of CME/CNE content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME/CNE activity content over which the individual has control.

Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education, LLC, is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide 1.25 contact hours for nurses.

This enduring material is approved for 1 year from the date of original release, April 5, 2019 to April 4, 2020.

Instructions for Receiving Credit

To participate in this CME/CNE activity, you must read the objectives, answer the pretest questions, watch the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Learner-Paced Continuing Nursing Education Contact Hour Certificate.

MIPS Qualifying Activity

Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Contact Information for Questions about the Activity

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME/CNE Questions?
Contact us at CME@VindicoCME.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME
The France Foundation
Spinal Muscular Atrophy Expert Discussion Conference Series — Questions About SMA Treatment

Spinal Muscular Atrophy Expert Discussion Conference Series — Questions About SMA Treatment

Start

Conference Series: Part 3 of 3

Activity Details

Free CME
0.50 AMA PRA Category 1 Credit(s)
Released: August 21, 2018
Expires: August 20, 2019
30 minutes to complete

Accredited By

Target Audience

Neurologists, pediatric neurologists, neuromuscular specialists, pediatricians, genetic counselors, and other clinicians who see patients with spinal muscular atrophy

Learning Objectives

  • Explain the genetic aspects of SMA, including its recessive nature, carriers, and recommendations for genetic screening
  • Explore the potential implications of gene therapy for SMA
  • Summarize key clinical trial data on available/ emerging treatments for SMA

Activity Description

As new therapies emerge for spinal muscular atrophy (SMA) that include gene replacement and gene modifying therapies, clinicians need to consider the expectations for these treatments. Experts, Dr. Eugenio Mercuri, Dr. Richard Finkel, and Dr. Gyula Acsadi, recently discussed these emerging therapies and their implications on the clinical disease state at an international meeting. This activity is a recording of their roundtable discussion with informative slides broken into 3 parts. The first part discusses diagnosis, genetics, and the role of SMN in SMA. Part 2 explains the results of emerging clinical trial data. The final activity is a practical discussion about the implications of these new therapies for this lethal disease. Discussion topics include the durability of new and emerging treatments and changes to the standards of care for patients with SMA. This education is an engaging update on SMA from the leading experts in the field.

Statement of Educational Need

Many clinicians have questions regarding the genetics of spinal muscular atrophy. In addition, carrier screening is not routinely done, despite ACOG recommendations. Routine newborn testing is currently being considered in many states and internationally. Identification of the neuromotor deficits associated with SMA (and other conditions) is often inaccurate or delayed. As new therapies emerge that include gene replacement and gene modifying therapies, clinicians need to consider the expectations of these treatments. Gene replacement therapy is still a mystery to most clinicians. New therapies prompt a reevaluation of current standards of SMA care.

Agenda

  • What do we know and what do we need to know about treatments?
  • Questions from the audience

Faculty

Eugenio Mercuri, MD, PhD (Chair)
Professor of Pediatric Neurology
Catholic University of the Sacred Heart
Rome, Italy

Dr. Eugenio Mercuri is a consultant for AveXis, Biogen, F. Hoffmann-La Roche, and IONIS. He is a principal investigator for Biogen/IONIS and F. Hoffmann-La Roche studies.


Richard S. Finkel, MD
Division Chief of Neurology
Pediatric Neurology
Nemours Children’s Hospital
Orlando, Florida, United States

Dr. Richard Finkel is a consultant for AveXis, Biogen, Catabasis, Ionis, Mitobridge, Novartis, and Roche. He receives clinical trial support from AveXis, Biogen, Catabasis, Cytokinetics, Ionis, Lilly, MDA, NIH, ReveraGen, and Summit. Dr. Finkel owns stock in Roche. His partner holds several patents and receives patent licensing royalties from National Jewish Center and Children’s Hospital of Philadelphia.


Gyula Acsadi, MD, PhD
Division Head of Neurology and Rehabilitation
Professor of Pediatric Neurology
Connecticut Children’s Medical Center
University of Connecticut Medical School
Hartford, Connecticut, United States

Dr. Gyula Acsadi serves as a consultant for AveXis, Biogen, and Serepta. He is on the speakers bureau for Biogen and conducts contract research for Biogen, Italfarmaco, and Serepta.


Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest

Activity Staff Disclosure

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME information.
  • Complete the CME activity
  • Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis, Inc.

Disclaimer Statement

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.75 CME
The France Foundation
SMA Management: Data, Insights and Practice

SMA Management: Data, Insights and Practice

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: December 7, 2018
Expires: December 6, 2019
45 minutes

Accredited By

Target Audience

Pediatric neurologists, neurologists, neuromuscular specialists, pediatricians

Learning Objectives

  • Review new information on the management of patients with SMA released at the Child Neurology Society and World Muscle Society 2018 annual meetings
  • Apply new information to current SMA management practices, as relevant

Activity Description

This education provides the opportunity to learn the latest in the management of patients with Type 1 or Type 3 spinal muscular atrophy (SMA). Abstracts of posters from recent neurology meetings are presented followed by video discussions by expert faculty regarding the implication on the management of patients. Skills can then be applied in an interactive case where the learner is challenged to make decisions for a patient with Type 1 or Type 3 SMA. 

Statement of Educational Need

The recent, rapid influx of information surrounding approved and emerging treatments for spinal muscular atrophy (SMA) has created a gap in clinician knowledge and the ability to apply it to practice.

Agenda

Type 1 SMA abstracts
NURTURE Update in Presymptomatic Patients (3:35)
Dr. Nancy Kuntz and Dr. Richard Finkel
Improvement for Patients in ENDEAR Study (4:07)
Dr. Nancy Kuntz and Dr. Richard Finkel
Type 1 interactive case

Type 3 SMA abstracts
Results in Type 3 Patients Treated with Nusinersen (3:05)
Dr. Richard Finkel, Dr. Nancy Kuntz, and Dr. Gyula Acsadi
A Multidisciplinary Team is Essential to the Management of SMA (2:08)
Dr. Thomas Crawford and Dr. Laurent Servais
Type 3 interactive case

Faculty

Gyula Acsadi, MD, PhD
Division Head of Neurology and Rehabilitation
Professor of Pediatric Neurology
Connecticut Children’s Medical Center
University of Connecticut Medical School
Farmington, Connecticut


  • Dr. Gyula Acsadi serves as a consultant for AveXis, Biogen, and Sarepta. He is on the speakers bureau for Biogen and conducts contract research for Biogen, Italfarmaco, and Sarepta.

Thomas Crawford, MD
Co-Director, Muscular Dystrophy Association Clinic
Professor of Neurology
Johns Hopkins Medicine
Baltimore, Maryland


  • Dr. Crawford serves as a consultant and is on the advisory boards for AveXis, Inc., Biogen, Mallinckrodt, Marathon, Roche/Genentech, Santhera, and Scholar Rock.

Richard S. Finkel, MD
Division Chief of Neurology
Pediatric Neurology
Nemours Children’s Hospital
Orlando, Florida


  • Dr. Richard Finkel is a consultant for AveXis, Biogen, Catabasis, Ionis, Mitobridge, Roche, and Novartis. He receives clinical trial support from AveXis, Biogen, Ionis, Catabasis, Cytokinetics, Lilly, MDA, NIH, ReveraGen, and Summit. Dr. Finkel owns stock in Roche. His partner holds several patents and receives patent licensing royalties from National Jewish Center and Children’s Hospital of Philadelphia.

Nancy L. Kuntz, MD
Professor of Pediatrics and Neurology
Northwestern University Feinberg School of Medicine
Attending Physician
Division of Neurology
Ann & Robert H. Lurie Children’s Hospital of Chicago
Chicago, Illinois


  • Dr. Kuntz serves on clinical advisory boards for Audentes, AveXis, Inc., Biogen, Roche, and Sarepta. She has participated in educational lectures funded by Biogen.

Laurent Servais, MD, PhD
Pediatric Neurology
Institut de Myologie
Paris, France


  • Dr. Servais serves on advisory boards for AveXis, Inc., Biogen, and Roche. He is a principle investigator for projects funded by AveXis, Inc., Biogen, and Roche.

Conflict of Interest Policy/Disclosure Statement

Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity
  • Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credit(s)™ or a certificate of participation—your CME/CE certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.75 CME
The France Foundation
Conference Updates in SMA

Conference Updates in SMA

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credits
Released: November 6, 2018
Expires: November 5, 2019
45 minutes to complete

Accredited By

Target Audience

Pediatric Neurologists, Neurologists, Neuromuscular Specialists, Pediatricians

Learning Objectives

  • Review new information on the management of patients with SMA released at the Child Neurology Society and World Muscle Society 2018 annual meetings
  • Apply new information to current SMA management practices, as relevant

Activity Description

Experts in spinal muscular atrophy (SMA) attended October neurologic and neuromuscular meetings. These short videos share the exciting information from the meetings in easily digestible segments with insight in how this new information may change the management of patients with SMA.

Statement of Educational Need

The recent, rapid influx of information surrounding approved and emerging treatments for spinal muscular atrophy (SMA) has created a gap in clinician knowledge and the ability to apply it to practice.

Agenda

New Therapies are Changing the Outcomes of SMA (2:53)
Dr. Thomas Crawford

NURTURE Update in Presymptomatic Patients (3:35)
Dr. Nancy Kuntz and Dr. Richard Finkel

Nusinersen Treated Type 1 Patients Older Than 7 Months (4:18)
Dr. Laurent Servais

Results in Type 3 Patients Treated with Nusinersen (3:05)
Dr. Richard Finkel, Dr. Nancy Kuntz, and Dr. Gyula Acsadi

A Multidisciplinary Team is Essential to the Management of SMA (2:08)
Dr. Thomas Crawford and Dr. Laurent Servais

Updates on SMA from Chicago (4:20)
Dr. Richard Finkel

SMA Poster Highlights from Mendoza (4:43)
Dr. Laurent Servais

How a Neurofilament Biomarker Could Change SMA Management (6:41)
Dr. Thomas Crawford

Improvement for Patients in ENDEAR Study (4:07)
Dr. Nancy Kuntz and Dr. Richard Finkel

Emerging Data from Gene Therapy Trials (2:44)
Dr. Richard Finkel and Dr. Gyula Acsadi

Oral Small Molecules as an Emerging Therapy for SMA (3:45)
Dr. Richard Finkel

Caution in Counseling Patients with SMA (3:12)
Dr. Thomas Crawford and Dr. Laurent Servais

Early Diagnosis and Treatment are Essential (4:23)
Dr. Gyula Acsadi, Dr. Nancy Kuntz, and Dr. Richard Finkel

Faculty

Gyula Acsadi, MD, PhD
Division Head of Neurology and Rehabilitation
Professor of Pediatric Neurology
Connecticut Children’s Medical Center
University of Connecticut Medical School
Farmington, Connecticut
  • Dr. Acsadi serves as a consultant for AveXis, Biogen, and Sarepta. He is on the speakers bureau for Biogen and conducts contract research for Biogen, Italfarmaco, and Sarepta.


Thomas Crawford, MD
Co-Director, Muscular Dystrophy Association Clinic
Professor of Neurology
Johns Hopkins Medicine
Baltimore, Maryland
  • Dr. Crawford serves as a consultant and is on the advisory boards for AveXis, Biogen, Mallinckrodt, Marathon, Roche/Genentech, Santhera, and Scholar Rock.


Richard S. Finkel, MD
Division Chief of Neurology
Pediatric Neurology
Nemours Children’s Hospital
Orlando, Florida
  • Dr. Finkel is a consultant for AveXis, Biogen, Catabasis, Ionis, Mitobridge, Roche, and Novartis. He receives clinical trial support from AveXis, Biogen, Ionis, Catabasis, Cytokinetics, Lilly, MDA, NIH, ReveraGen, and Summit. Dr. Finkel owns stock in Roche. His partner holds several patents and receives patent licensing royalties from National Jewish Center and Children’s Hospital of Philadelphia.


Nancy L. Kuntz, MD
Professor of Pediatrics and Neurology
Northwestern University Feinberg School of Medicine
Attending Physician
Division of Neurology
Ann & Robert H. Lurie Children’s Hospital of Chicago
Chicago, Illinois
  • Dr. Kuntz serves on clinical advisory boards for Audentes, AveXis, Biogen, Roche, and Sarepta. She has participated in educational lectures funded by Biogen.


Laurent Servais, MD, PhD
Pediatric Neurology
Institut de Myologie
Paris, France
  • Dr. Servais serves on advisory boards for AveXis, Biogen, and Roche. He is a principle investigator for projects funded by AveXis, Biogen, and Roche.


Conflict of Interest Policy/Disclosure Statement

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Instructions for Receiving Credit

  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME/CE information.
  3. Complete the CME/CE activity.
  4. Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
  6. Credit documentation/reporting:

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Disclaimer

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.75 CME / CNE
Vindico
Highlights from MS Forum® V

Highlights from MS Forum® V

Start

Activity Details

Free CME/CNE
1.75 AMA PRA Category 1 Credit(s)
1.75 Contact Hours
Released: December 31, 2018
Expires: December 31, 2019
1.75 hours to complete

Accredited By

Endorsed By

Target Audience

The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the treatment of patients with multiple sclerosis (MS).

Purpose/Learning Objectives

Upon successful completion of this activity, participants should be better able to:
Physician

  • Assess the latest clinical evidence regarding available and emerging DMTs for MS management.
  • Identify patients with progressive MS in a timely manner to ensure appropriate intervention.
  • Select treatment for patient with RRMS or progressive MS based on the latest clinical advances and evidence-based guidelines.

Nurse

  • Assess the latest clinical evidence regarding available and emerging DMTs for MS management.

Activity Description

This CME/CNE activity is based on the slides and lectures presented by the faculty at the live program, “MS Forum® V: Applying Clinical Advances and Shared Decision-making to Improve Quality Care,” on October 27, 2018 at the JW Marriott Chicago in Chicago, IL.

Statement of Educational Need

Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. The management of patients with MS is highly complex and the development of disease-modifying therapies (DMTs) has dramatically altered the treatment paradigm. Guidelines from the American Academy of Neurology on the use of DMTs were just released in 2018 and clinicians need to be updated on these new evidence-based recommendations. In this CME/CNE activity, Highlights from MS Forum®V, current treatment guidelines, safety, efficacy, and use of current DMTs will be discussed.

Agenda

What Do the New Guidelines Mean for Your Practice?
Updates in DMTs: Clinical and Practical Review
Updates in Progressive MS: Recognition and Management

Faculty

Activity Chair:
Patricia K. Coyle, MD, FAAN, FANA
Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosures:Consulting Fee: Accordant, Acorda, Bayer, Biogen, Celgene, Genentech/Roche, Genzyme/Sanofi, Novartis, Serono, Teva
Contracted Research: Actelion, Alkermes, Genentech/Roche, MedDay, NINDS, Novartis


Steering Committee & Faculty:
Guy J. Buckle, MD, MPH
Guy J. Buckle, MD, MPH
Director of Neuroimaging Research
MS Center at Shepherd Center
Atlanta, GA

Disclosures:Consulting Fee: Biogen, Celgene, EMD Serono, Genentech, Novartis, Sanofi Genzyme, Teva
Speakers Bureau: Biogen, EMD Serono, Genentech, Novartis, Sanofi Genzyme, Teva


Bruce A. Cohen, MD, FAAN, FANA, FACP
Bruce A. Cohen, MD, FAAN, FANA, FACP
Professor of Neurology
Northwestern University
Feinberg School of Medicine
Director
Northwestern Comprehensive Multiple Sclerosis Program
Chicago, IL

Disclosures:Consulting Fee: EMD Serono, Mylan, Novartis
Contracted Research (Paid to Institution): Genentech/Hoffman LaRoche, MedDay, Novartis


Clyde E. Markowitz, MD
Clyde E. Markowitz, MD
Associate Professor of Neurology
Director, Multiple Sclerosis Center
Hospital of the University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA

Disclosures:Consulting Fee: Bayer, Biogen, Celgene, EMD Serono, Novartis, Roche/Genentech, Sanofi/Genzyme, Teva


Harold Moses, MD
Harold Moses, MD
Associate Professor of Neurology
Vanderbilt University
Nashville, TN

Disclosures:Consulting Fee: Bayer, Biogen, Celgene, EMD Serono, Genzyme, Novartis, Teva
Speakers Bureau: Biogen, EMD Serona, Genzyme, Teva
Contracted Research: MedDay


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Nurse Planners:
Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Contracted Research: Celgene, Genentech, Genzyme, Mallinckrodt, Novartis, Roche
Speakers Bureau: Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Teva

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

Vindico Medical Education Staff: No relevant financial relationships to disclose.

Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education, LLC is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide 1.75 contact hours for nurses.

Instructions for Receiving Credit

To participate in this CME/CNE activity, you must read the objectives, answer the pretest questions, review the CME/CNE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Provider-Paced Contact Hours Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Genentech, Inc. and Novartis Pharmaceuticals, Inc.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/ Disclosure of Unlabeled Use

The material presented at or in any Vindico Medical Education and CMSC continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education and CMSC. Neither Vindico Medical Education, CMSC, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the U.S. Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

CME@VindicoCME.com
Call us at 856-994-9400 x504

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME
Forefront Collaborative
Rethinking Migraine Treatment: Highlights and Recent Advances

Rethinking Migraine Treatment: Highlights and Recent Advances

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: December 11, 2018
Expires: December 10, 2019
15 minutes to complete

Accredited By

Target Audience

This activity is designed for general neurologists and headache specialists. Other healthcare professionals, including physician assistants, nurse practitioners, nurses, and pharmacists, who treat patients with headache may also benefit from participation in the educational activity.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe new advances in the pathophysiology of migraine, a chronic neurologic disease.
  • Describe major emerging acute and preventive migraine therapies.

Activity Description

Paradigm shift, or shattered? The thinking around both preventive and acute treatment of migraine is amidst a radical change. From a new class of treatment targeting disease-specific pathophysiology to emerging therapies incorporating neuromodulatory devices, Stewart Tepper, MD, gets practicing clinicians up to speed in a Hot Topics Webinar that details the key treatment advances transforming migraine care.

Statement of Educational Need

With the recent approvals of new breakthroughs, neurologists are faced with two challenges: staying abreast of the rapidly expanding evidence base to inform acute and preventive treatment of migraine (knowledge-based gaps) and interpreting data of approved and investigational therapies to best guide clinical decision-making (competency-based gaps).

Agenda

New Horizons in Headache Treatment
Pathophysiology and Neurotransmitter Targets
New Devices and Medications for Delivering Medications
New Acute Treatment Classes
Prevention: MABs
Neuromodulation for Headache

Faculty

Stewart J. Tepper, MD
Stewart J. Tepper, MD
Professor of Neurology
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire


Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Faculty: Stewart J. Tepper, MD, has received salary from Dartmouth-Hitchcock Medical Center and from the American Headache Society and royalties from Springer; he has been a consultant or on an advisory board for Acorda Therapeutics, Alder BioPharmaceuticals, Alexza Pharmaceuticals, Allergan, Alphasights, Amgen, Autonomic Technologies, Axsome Therapeutics, Cefaly, Charleston Laboratories, DeepBench, Dr. Reddy’s Laboratories, electroCore, Eli Lilly and Company, eNeura, GLG Pharma, Guidepoint Global, Magellan Rx Management,  Neurolief, Nordic BioTech, Pfizer, Scion Neurostim, Slingshot Insights, Supernus Pharmaceuticals, Teva Pharmaceutical Industries, and Zosano Pharma Corporation; Dr. Tepper has contracted research for Alder BioPharmaceuticals, Allergan, Amgen, Autonomic Technologies, Dr. Reddy’s Laboratories, electroCore, eNeura, Scion Neurostim, Teva Pharmaceutical Industries, and Zosano Pharma Corporation; he has ownership interest in Autonomic Technologies.
  • Planner (Forefront Collaborative): Lily Zurkovsky, PhD, has disclosed that she has personal stock in Teva Pharmaceutical Industries.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this continuing education activity:

  • Planner (Forefront Collaborative): Katie Detzler

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Forefront Collaborative designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

Participants must complete and submit the online CME evaluation form at the conclusion of the activity and achieve a passing score of 3 out of 3. Certificates will be generated upon completion and submission of the evaluation form.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.

Content Review Statement

The content of this activity was independently peer reviewed. The reviewer of this activity has no relevant financial relationships to disclose.

This continuing medical education activity will include reference to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions about the Activity

Lily_Zurkovsky@forefrontcollab.com
317.846.2770

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.50 CME
The France Foundation
From Bench to Bedside: Gene Therapy Approaches for Rare Diseases

From Bench to Bedside: Gene Therapy Approaches for Rare Diseases

Start

Activity Details

Free CME
1.50 AMA PRA Category 1 Credit(s)
Released: November 15, 2018
Expires: November 14, 2019
90 minutes to complete

Accredited By

Target Audience

Pediatric Neurologists, Neurologists, Neuromuscular Specialists, Pediatricians

Learning Objectives

  • Understand importance of early diagnosis for inherited neuromuscular diseases
  • Explore potential implications of gene therapy
  • Summarize key clinical trial data on emerging gene therapies
  • Provide appropriate counseling to affected individuals and families

Activity Description

Gene replacement therapy is emerging as a potential treatment for rare CNS diseases. In this recorded CME satellite symposium to the 2018 Child Neurology Society’s annual meeting, a parent of a child with spinal muscular atrophy describes their journey through gene therapy clinical trials. Using spinal muscular atrophy as an example, Dr. Samiah Al-Zaidy, Mr. Jaysson Eicholtz and Dr. Jerry Mendell walk through the history of gene therapy from the bench to the bedside, answering questions on safety and long-term durability of this emerging treatment.

Statement of Educational Need

Gene replacement therapy is showing promising results for several neurologic diseases. Clinicians must be comfortable with this technology before it comes to the clinic. Delayed diagnosis is a common problem with spinal muscular atrophy, even when specialists are involved. Identification of the neuromotor deficits associated with SMA (and other inherited neuromuscular diseases) is often inaccurate or delayed. Prompt diagnosis and treatment is crucial in the effectiveness of gene replacement therapy. These emerging new therapies prompt a reevaluation of current standards of care for patients with SMA and appropriate counseling to the affected individuals and families.

Agenda

Introduction (Dr. Samiah Al-Zaidy)
Patient Journey Video: Meet the Villarreal family
History of Gene Therapy and the Current Landscape (Dr. Samiah Al-Zaidy)
Patient Journey Video: Diagnosis
Bringing the Vector to the Clinic (Mr. Jaysson Eicholtz)
Patient Journey Video: Treatment
Gene Therapy Clinical Trials: the Epitome of Personalized Medicine (Dr. Jerry Mendell)
Patient Journey Video: Results
Gene Therapy Clinical Trials: Part 2 (Dr. Jerry Mendell)
Panel Discussion (Dr. Samiah Al-Zaidy, Dr. Jerry Mendell, Mr. Jaysson Eicholtz)
Patient Journey Video: Living with SMA
Focus on Patient-Centered Care (Dr. Samiah Al-Zaidy, Dr. Jerry Mendell)

Faculty

Samiah Al-Zaidy, MD
Pediatric Neuromuscular Specialist
Formerly of Nationwide Children’s Hospital
Columbus, OH
  • Dr. Al-Zaidy serves as a consultant for AveXis, Inc.


Jaysson Eicholtz, MS
Former Director of GMP Operations
Nationwide Children’s Hospital
Columbus, OH
  • Mr. Eicholtz has no relevant financial relationships to disclose.


Jerry Mendell, MD
Curran-Peters Chair of Pediatric Research
Professor of Pediatrics and Neurology
Nationwide Children’s Hospital and
The Ohio State University
Research Institute at Nationwide Children's Hospital
Columbus, OH
  • Dr. Mendell serves as a consultant to AveXis, Inc., Exonics, Myonexus, and Sarepta Therapeutics. He is the principal investigator of the AVXS-101 gene therapy clinical trial, the Eteplirsen clinical trial, and an advisor on the CRISPR clinical trial.


Conflict of Interest Policy/Disclosure Statement

Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity
  • Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from AveXis, Inc.

Disclaimer

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.50 CME
Vindico
Managing Off Episodes in Patients With Parkinson’s Disease: Unmet Needs and Emerging Options

Managing Off Episodes in Patients With Parkinson’s Disease: Unmet Needs and Emerging Options

Start

Activity Chair

Mark F. Lew, MD, FAAN
Professor of Neurology
Director, Division of Movement Disorders
Vice-Chair, Department of Neurology
VanDerMeulen Chair in PD Research
Keck/USC School of Medicine
Los Angeles, CA

Disclosure: Consulting Fee: Adamas, AbbVie, Acadia, Cynapsus, Lundbeck, Neurocrine, Prexton, Revance, Teva, UCB, US WorldMeds
Speakers Bureau: Acadia, Adamas, Lundbeck, Neurocrine, Teva, UCB
Contracted Research: Acorda, Biotie, Enterin, Michael J. Fox Foundation,NeuroDerm, Parkinson's Study Group, Pharm2B

Faculty

Rajesh Pahwa, MD
Laverne & Joyce Rider Professor of Neurology
Chief, Parkinson & Movement Disorders Division
Director, Parkinson Foundation Center of Excellence
University of Kansas Medical Center
Kansas City, KS

Disclosure: Consulting Fee: Abbott Medical Optics, AbbVie, Acorda, Adamas, Sunovion, US WorldMeds
Speakers Bureau: AbbVie, Acorda, Sunovion
Contracted Research: Abbott Medical Optics, AbbVie, Acorda, Adamas, Bristol-Myers Squibb, Boston Scientific, Cala Health, Cavion, Cynapsus, Intec, Jazz, Kyowa, Lilly, Pfizer, Prexton, Roche, Sunovion, US WorldMeds

Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff

Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accredited By

This continuing medical education activity is provided by Vindico Medical Education.

Activity Details

Free CME
0.5 AMA PRA Category 1 Credits
Released: August 30, 2018
Expires: August 30, 2019
0.5 hour to complete

Activity Description

Parkinson's disease is a progressive, chronic, neurodegenerative disorder that affects more than 10 million people worldwide. It is canonically regarded as a hypokinetic motor condition, with bradykinesia, resting tremor, and rigidity as its classic features. However, neuropsychiatric and other nonmotor symptoms can have a greater impact on patients’ quality of life. In early disease, the motor symptoms of many patients can be controlled with the use of levodopa. However, many patients gradually experience “off episodes” in which symptoms re-emerge, often in a severe and long-lasting form. This wearing-off effect of treatment can further reduce quality of life, but treatment options are limited. This CME activity will feature a panel discussion with 2 expert clinicians, who will assess recent therapeutic updates in the treatment of patients with Parkinson’s disease and the latest strategies to manage these off episodes.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the prevalence and burden of off episodes associated with Parkinson's disease
  • Identify patients with Parkinson's disease who are experiencing off episodes and adjust the care plan accordingly
  • Assess the latest clinical advances regarding available and emerging options for the management of off episodes in patients with Parkinson's disease

Target Audience

The intended audience for the activity is neurologists and other health care professionals involved in the treatment of patients with Parkinson's disease.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credits™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

Contact us at CME@VindicoCME.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Pages